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8INTRODUCTION
Meningiomas and schwannomas are common primary intracranial and spinal tumors.
They occur either as single sporadic tumors or as multiple tumors in association with the
autosomal dominant genetic disorder neurofibromatosis 2 (NF2). NF2 predisposes the patient
at an early age to multiple schwannomas (bilateral vestibular), meningiomas, and spinal
ependymomas. NF2 is caused by a mutation in the NF2 tumor suppressor gene, which is also
involved in the tumorigenesis of sporadic meningiomas and schwannomas. The diagnosis of
NF2 is not always clear since there is a heterogeneous and poorly defined group of patients who
do not have bilateral vestibular schwannomas (BVSs) but present with other features suggestive
of NF2, namely (1) multiple meningiomas or schwannomas, and/or (2) meningioma(s) or
schwannomas(s) in their relatives. These patients are rather uncommon but they are problematic
in terms of prognosis, therapy, follow-up, and genetic counseling.
In sporadic patients, schwannomas and meningiomas usually appear as single, slowly
growing tumors in the fourth to sixth decades of life, mostly curable by radical surgery, and
multiple schwannomas and meningiomas are rare. In NF2, schwannomas and meningiomas
are multiple, occur earlier in life and have a more aggressive clinical course than those in
sporadic cases. Histological comparisons of surgically removed sporadic and NF2-associated
vestibular schwannomas have shown that the latter are more often lobular and tend to
infiltrate the adjacent facial nerve. Consequently, preservation of the continuity and function of
the facial and cochlear nerves during surgery is more difficult in NF2 tumors.
This thesis focuses on the comparison of sporadic and NF2-associated schwannomas
and meningiomas. The proliferation potential and histological features are compared, and
possible differences in genetic aberrations between NF2 and sporadic schwannomas are
searched. A population-based estimate is made of the proportion of meningiomatosis and
schwannomatosis among patients with single tumors, and of their relation to NF2.
91 REVIEW OF THE LITERATURE
1.1 Hereditary Cancer Syndromes
1.1.1 Overview and Significance
The vast majority of mutations in cancer are somatic and are found only in the cancer
cells. About 1% of all cancers are related to a hereditary cancer syndrome in which the
affected individual carries the particular germline mutation in every cell of his/her body49.
More than 20 hereditary cancer syndromes have been defined and attributed to specific
germline mutations in various, mostly dominantly inherited, cancer genes49. The major
hereditary cancer syndromes with manifestations in the nervous system are listed in Table 1.
Each syndrome is distinct, with its own unique spectrum of nervous system neoplasms,
systemic neoplasms, and non-neoplastic lesions. Although hereditary cancer syndromes are
rare, their study has provided important insights into more common forms of cancer. Somatic
mutations in sporadic cancers frequently affect inherited cancer genes, and studies of such
genes have yielded novel information about cell signaling pathways.
1.1.2 Tumor Suppressor Genes
Cancer appears to result from the accumulation of multiple genetic alterations99,179.
It is now generally accepted that the progression of a tumor to full malignancy often requires
both the activation of dominantly acting oncogenes and the inactivation of tumor suppressor
genes. Most of the genes responsible for hereditary cancer syndromes are tumor suppressor
genes. Tumor suppressor genes inhibit cell proliferation and growth59,103,121. The loss or
inactivation of these genes results in tumor formation or progression. Recently, tumor
suppressor genes have been subdivided into gatekeepers and caretakers, the former being
genes that regulate tumor growth directly by inhibiting cell proliferation or promoting cell
death, whereas the latter are genes whose inactivation causes genetic instability which in turn
leads to mutations that promote tumor growth85.
The existence of genes that suppress the neoplastic phenotype was first suggested by
Harris et al., who showed that fusion of tumor cells with normal cells results in outgrowth of
nontumorigenic hybrid cells62. In 1971 Knudson presented his now classic two-hit hypothesis
which explained the features of hereditary cancer syndromes90,91. His model was based on
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epidemiological analyses of the age of onset of multifocal (familial) versus single (sporadic)
cases of retinoblastoma. For familial retinoblastoma, the model implies that the patient
inherits the first hit (mutation), and only one somatic hit during the patient's life is required for
tumor formation. For sporadic retinoblastoma, two somatic mutational events are needed,
which explains the later age of onset in these patients. Genetic analysis of blood and tumor
DNA pairs, loss of heterozygosity (LOH) analyses9,27, and the isolation of the retinoblastoma
gene96 eventually confirmed Knudson's theory. Despite the genetic "recessiveness" of tumor
suppressor genes, the high likelihood of a second hit in at least one susceptible cell causes the
apparent dominant inheritance pattern of familial cancer syndromes, the appearance of cancer
at an earlier age than usual, and the frequent multiplicity of tumors associated with these
syndromes111. Although particular mutant alleles of inherited cancer genes are associated
with the age of onset, severity, and types of cancer in mutation carriers, it has become clear
that other modifier genes and dietary, environmental, and lifestyle factors substantially modify
the expression of cancer in mutation carriers49,99.
The products of tumor suppressor genes are involved in a variety of cellular functions.
These proteins appear to function as transmembrane receptors (PTCH), cytoplasmic
regulatory or structural proteins (NF1, PTEN, APC, NF2) or transcription factors or regulators
of transcription (p53 and VHL)49 (Table 1).
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Table 1
Familial Cancer Syndromes with Major Manifestations in the Nervous System (from Kleihues et al. 199787 and OMIM = Online Mendelian
Inheritance in Man, http://www.ncbi.nlm.nih.gov/Omim/).
Syndrome
MIM No.a
Gene Chromosomal
Location
Protein Function Nervous System
Tumors
Other Lesions
Neurofibromatosis 1
162200
NF1 17q11 GTPase-activating
protein
Neurofibroma, MPNST,
optic nerve glioma,
astrocytoma
Café-au-lait spots, axillary freckling, iris
hamartoma, osseous lesions,
pheochromocytoma, leukemia
Neurofibromatosis 2
101000
NF2 22q12 Cytoskeletal-
membrane linkage
BVSs, meningioma,
ependymoma, peripheral
schwannoma
Posterior lens opacities, retinal hamartoma
von Hippel-Lindau
193300
VHL 3p25 Elongation factor Hemangioblastoma Retinal hemangioblastoma, renal cell
carcinoma, pheochromocytoma, visceral cysts
Tuberous sclerosis
191100
191092
TSC1
TSC2
9q34
16p13
Not known
GTPase-activating
protein
Subependymal giant cell
astrocytoma, cortical tubers
Facial angiofibroma, periungual fibroma,
cardiac rhabdomyoma,
lymphangioleiomyomatosis, renal
angiomyolipoma
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Li-Fraumeni
151623
p53 17p13 Transcription factor Astrocytomas, PNET Breast carcinoma, bone and soft tissue
sarcomas, adrenocortical carcinoma, leukemia
Cowden
158350
PTEN 10q23 Cytoplasmic
regulatory protein
Dysplastic gangliocytoma
of the cerebellum
(Lhermitte-Duclos)
Multiple facial trichilemmomas,
hamartomatous polyps of the  colon, thyroid
neoplasms, breast cancer
Turcot
276300
APC
hMLH1
hPSM2
5q21
3p21
7p22
Signal transduction
DNA mismatch
repair
DNA mismatch
repair
Medulloblastoma
Glioblastoma
Colorectal polyps
Café-au-lait spots, colorectal polyps
Nevoid Basal Cell
Syndrome (Gorlin)
109400
PTCH 9q31 Transmembrane
receptor
Medulloblastoma Multiple basal cell carcinomas, jaw cysts,
skeletal malformations
aOMIM reference number
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1.2 Neurofibromatosis 2
1.2.1 Historical Aspects
The term neurofibromatosis actually encompasses two distinct genetic diseases.
Neurofibromatosis 2 (NF2), previously known as central neurofibromatosis, is a rare
(1/40,000 live births) autosomal dominant disorder predisposing the carrier to multiple
schwannomas, meningiomas, and spinal ependymomas, with BVSs as its classic diagnostic
hallmark57,110. For comparison, neurofibromatosis 1 (NF1), previously known as peripheral
or von Recklinghausen's neurofibromatosis, is a common (1/4,000 live births), autosomal
dominant disorder characterized by multiple neurofibromas in peripheral nerves, café-au-lait
spots, optic nerve gliomas and other astrocytomas, iris hamartomas, and osseous lesions33,57.
Probably the first case report of NF2 was published by Wishart in 182243. This patient
had multiple intracranial tumors with no reported cutaneous features. In 1882, the German
neuropathologist Friedrich von Recklinghausen (1833-1910) described five patients with a
nodular skin lesion and no intracranial tumors150. In subsequent studies, these two entities
(NF1 and NF2) were combined and referred to as von Recklinghausen's disease. In reporting a
large family with NF2 in 1930, Gardner and Frazier suggested that bilateral acoustic neuromas
represent a separate central form of von Recklinghausen's neurofibromatosis53. In 1987, the
National Institutes of Health (NIH) Consensus Statement on Neurofibromatosis introduced the
basis for the present diagnostic criteria of neurofibromatosis, clearly separating NF1 and NF2
and recommending the use of the term neurofibromatosis 1 rather than peripheral or von
Recklinghausen's neurofibromatosis and the term neurofibromatosis 2 rather than central or
bilateral acoustic neurofibromatosis133. Also in 1987, mapping of the gene for NF1 to
chromosome 175,172 and that for NF2 to chromosome 22155,170 confirmed the clinical
impression of two distinct diseases. The NF1 gene, encoding neurofibromin, on the long arm
of chromosome 17 (17q12) was cloned in 1991119. The NF2 gene, encoding merlin or
schwannomin, on chromosome 22 (22q12) was cloned in 1993154,189.
1.2.2 Clinical Aspects
The present diagnostic criteria for NF2 are as follow43,57,133:
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1. BVSs, or
2. a first-degree relative with NF2, and either (a) unilateral vestibular schwannoma or
(b) any two of the following: meningioma, glioma, schwannoma, or juvenile posterior
subcapsular lenticular opacities/juvenile cortical cataract, or
3. two of the following: (a) unilateral vestibular schwannoma, (b) multiple
meningiomas, (c) either schwannoma, glioma, or juvenile posterior subcapsular
lenticular opacities/juvenile cortical cataract.
Mean age at the onset of symptoms has been estimated to be around 22 years and at
diagnosis 28 years43,135. Mean survival after diagnosis has been estimated at 15 years43. The
most common presenting symptom is hearing loss or tinnitus, but younger patients are more
likely to present with symptoms from other central nervous system (CNS) tumors or from
changes affecting the skin or eyes135. NF2 is clinically heterogenous, ranging from the mild
Gardner type (late onset; slowly-growing vestibular schwannomas; few other tumors) to the
aggressive Wishart type (early onset; multiple rapidly-growing tumors causing early
death)43,135. The natural history of NF2 is relatively consistent within families, whereas there is
marked interfamilial variation43. In about half the patients, there is no family history, the disease
being caused by a new spontaneous mutation43,135. The expression of NF2 seems to be more
severe when the mutation is inherited from an affected mother, and families with genetic
anticipation have been noted42,81.
BVSs are the classic diagnostic hallmark of NF2, affecting over 90% of patients. In
addition, asymptomatic and in most cases multiple spinal tumors (schwannomas,
meningiomas, and ependymomas) occur in about 90% of patients and should, therefore, also
be regarded as a hallmark of the disease38,40,123. Schwannomas and meningiomas are the
most frequent spinal tumors in NF260,125. Meningioma is the second most common
intracranial tumor in NF2, seen in 50-60% of cases and in multiple form in about 40% of
cases3,123,135. Lower cranial nerve (X and XII) schwannomas other than BVSs occur in
about 17% of patients123. Approximately 80% of gliomas in NF2 patients are intramedullary
spinal or cauda equina tumors, with further 10% of gliomas occurring in the medulla
oblongata38,122. Ependymomas account for approximately 65-75% of all histologically
diagnosed gliomas in NF2, and for almost all spinal gliomas95,122.
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The prevalence of skin tumors in NF2 is high and varies with disease severity, and
schwannomas predominate in sampled tumors124. Approximately 60% of NF2 patients have
skin tumors, which usually appear as flat dysplastic tumors or subcutaneous spherical nodular
tumors of the peripheral nerves, on the limbs and trunk124,135. Skin pigmentation (café-au-
lait spots) occurs in about 30% of patients with NF2124,135.
Ocular abnormalities occur frequently in patients with NF2. The most common ocular
abnormalities are posterior subcapsular or capsular, cortical, or mixed lens opacities,
encountered in about 60% of patients123,148. Retinal hamartomas and epiretinal membranes
occur in 9-22% of patients with NF2123,135,147.
The diagnosis of NF2 is based on clinical findings57. Predictive diagnosis by linkage
analysis using markers flanking the NF2 gene is possible in the vast majority of families with
two or more living affected individuals. Once a mutation has been identified in an affected
individual, a 100% specific test is then available for that family. However, mutation detection
is time-consuming and expensive and may not reveal the causative mutation. Standard
techniques detect only 60-70% of causative mutations even in classically affected
individuals47,136,158. This may be due to the fact that somatic mosaicism of the NF2 gene
seems to be a relatively common phenomenon in NF247,89. Mosaicism refers to the presence
of mutation in a subpopulation of cells: mixed cell populations with and without mutation in
the same individual10. A mutation may not be found in a case of NF2 if the patient is mosaic
for the mutation in such fashion that the leukocytes are unaffected. It has been estimated that
up to 15% of NF2 cases might have mosaicism preventing detection of the mutation in
blood47. Somatic mosaicism may account for the low detection rate off mutations in sporadic
NF2 cases and may explain the incomplete phenotypes in some of these patients47,89.
Verification of mosaicism may be possible by analyzing several tumors from the same
individual (an identical NF2 gene mutation in two or more tumors would be virtually
conclusive)47.
There seems to be some correlation between the type of NF2 mutation and clinical
severity of NF246,136,158. Patients with severe clinical disease tend to possess mutations that
produce a truncated protein (frameshift or nonsense mutations), whereas patients with milder
disease tend to have missense mutations or DNA alterations that are not spotted by
conventional mutation detection strategies. Exceptions to these general correlations have been
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reported. It has been suggested that the pronounced clinical heterogeneity reflects the
heterogeneity of the genetic mechanism underlying the development of NF221. Mosaicism
may partly explain the clinical heterogeneity of NF2. In previous clinical series the patients
were poorly MRI imaged and no good follow-up studies are available43,135, which also
explains the clinical heterogeneity of NF2.
1.2.3 Variants
There is a heterogeneous and poorly defined group of patients without BVSs but with
other features suggestive of NF2, namely (1) multiple meningiomas (meningiomatosis) or
schwannomas (schwannomatosis), and/or (2) meningioma(s) or schwannomas(s) in their
relatives. These cases, referred to as variants of NF2, are evidently rare but present problems for
prognosis, therapy, follow-up, and genetic counseling. Multiple tumors and familial cases may
be (1) coincidental but they may also represent (2) segmental NF2, i.e., a mosaically distributed
defect of the NF2 gene or, in theory, (3) a syndrome caused by another gene defect.
Schwannomatosis is a recently described distinct clinical entity, the genetic
background of which is still mainly unsolved. The clinical picture and course of
schwannomatosis has been well described recently175, but its occurrence and familiality in a
population is still unknown. The patient with schwannomatosis typically has multiple spinal,
peripheral nerve, or subcutaneous schwannomas, without BVSs, and the disease is segmental
or localized to a certain body part in approximately one-third of patients115,175.
Schwannomatosis is rarely familial, with familial cases often showing incomplete
penetrance73, which is in distinct contrast to NF2. Most patients with schwannomatosis are
middle aged at presentation175, clearly older than NF2 cases. Genetically, schwannomatosis
may include patients with: (1) a clinically very mild NF2; (2) segmental NF2; (3) or those
with a putative modifier gene defect on chromosome 22q, making the NF2 gene susceptible to
mutations without germ-line inactivation45,73. Jacoby et. al.73 has proposed the following
diagnostic criteria for schwannomatosis; these criteria have been used in the present study
(IV):
Definite schwannomatosis
1. two or more histopathologically diagnosed schwannomas plus
2. lack of radiographic evidence of vestibular schwannoma, at age >18 years.
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Presumptive or probable schwannomatosis
1. two or more histopathologically diagnosed schwannomas, without symptoms of
eighth nerve dysfunction, at age >30 years, or
2. Two or more histopathologically verified schwannomas in an anatomically limited
distribution (single limb or segment of the spine), without symptoms of eighth nerve
dysfunction, at any age.
Meningiomatosis is frequently associated with NF2 but can also occur sporadically in
individuals without any other NF2 features or family history. The proportion of patients with
multiple meningiomas has been 1-5% in surgical series23,34, and 8-16% in autopsy 149,201
and neuroradiological series112,131. There are several case reports on familial
meningiomatosis without NF2 (reviewed by Atkinson et al.4), but most of these studies were
done before the National Institutes of Health Consensus Statement on Neurofibromatosis and
will have included patients who would now be considered to have NF2. The prevalence of
familial meningiomatosis with no signs of NF2 in a population is unknown but the condition
is assumed to be very rare126. A family with multiple meningiomas has been reported that did
not show linkage to chromosome 22q, suggesting that NF2 and meningiomatosis may be
genetically distinct entities145.
The clinical picture of meningiomatosis, its relation to NF2, and the occurrence of
familial meningiomatosis in population are still equivocally presented in medical literature
and need clarification.
1.2.4 Epidemiology
Only one epidemiological study on NF2 has been published previously44. Evans et al.
found diagnostic prevalence of 0.47/100,000 and a birth incidence of 1/40,562 in a population
of 4,016,100 in the North West Region in England44.
1.2.5 Surgical Treatment
Surgical treatment of patients with NF2 is complex and probably should be limited to
special centers with experienced neurosurgeons. Preservation of hearing and the recovery of a
severed or sutured facial nerve after removal of vestibular schwannoma have been worse in
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NF2 than in patient with sporadic unilateral tumors13,14,20,165. This may be due to the
greater invasiveness and specific histological features of NF2 schwannomas compared with
unilateral tumors61,79,105,178. These characteristics and the bilateral nature of the disease
process, the decision to recommend surgery to a patient at a specific time is difficult. Samii et.
al. stated that surgery should be recommended to achieve two goals: (1) to decompress the
brain stem in case of life-threatening bilateral compression, and (2) to prolong the period of
functioning cranial nerves165. An early operation may save the patient's hearing from further
deterioration but, on the other hand, the operation may cause immediate loss of hearing. The
alternative is to wait until the affected ear is deaf. The decision is easier in known NF2
families, as the rate of progression is often similar in family members. Rapid tumor growth
and brain stem compression make surgery imperative. Small vestibular schwannomas can
often be resected completely, with a fair chance of preservation of both hearing and facial
nerve function57,165. Larger tumors are probably best managed by partial removal with
decompression performed when brain stem compression develops57,165,199. Stereotactic
radiotherapy might be an alternative for surgery in selected NF2 patients with small sized
vestibular schwannomas when progressive hearing loss or growth is documented185. Other
accessible cranial, spinal, and peripheral tumors should be removed when causing symptoms
or found in particularly risky locations, e.g., foramen magnum, especially if growth has been
recorded.
1.2.6 NF2 Tumor Suppressor Gene and Merlin (Schwannomin)
In 1986 and 1987, loss of heterozygosity and cytological studies in NF2 and sporadic
meningiomas and schwannomas have suggested the presence of a tumor suppressor gene on
chromosome 22170,171. This hypothesis was confirmed when molecular genetic analysis of a
large NF2 pedigree demonstrated linkage of NF2 to chromosome 22q12155. Additional
linkage studies narrowed down the location of the NF2 gene, and in 1993, the gene was
cloned by two independent groups154,189. Subsequent studies confirmed NF2 germline
mutations in individuals affected with NF2, and numerous somatic mutations were detected in
both NF2 and sporadic schwannomas and meningiomas, confirming the hypothesis of the NF2
gene functioning as a tumor suppressor12,16,17,31,72,74,75,97,114,128,129,159,162,195.
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NF2 gene defects also have been detected in non-NF2 tumors: mesotheliomas, and
occasionally in melanomas, colon carcinomas, and breast carcinomas56.
The wild-type NF2 gene spans 110 kb and comprises 17 exons55,56. The NF2 gene
product, merlin (for moesin-ezrin-radixin-like protein; also known as schwannomin), is a 595-
amino acid protein belonging to the protein 4.1 superfamily which includes moesin, ezrin,
radixin, erythrocyte protein 4.1, talin, and several tyrosine phosphatases191. The members of
the 4.1. superfamily have a common structure consisting of a large amino-terminal domain, a
central alpha-helical segment, and a charged carboxy-terminal domain118,191. Ezrin, radixin,
and moesin (the ERM family), with which merlin shares the most amino acid identity, are
cytoskeleton-associated proteins that act as structural links between the cytoskeleton and the
plasma membrane55,191. At least two major alternatively spliced merlin variants are
expressed in vivo55. Isoform 1, encoded by exons 1-15 and 17, has intramolecular interactions
similar to those of ERM proteins; isoform 2, encoded by exons 1-16, probably exists only in
an unfolded state. Merlin is expressed mainly in the nervous system, including Schwann cells,
neurons, astrocytes, and cells of the lens67,181. Merlin, like ERM proteins, is localized
underneath the cell membrane in regions of cellular extensions and partially co-localized with
CD44 and F-actin161,191. Merlin interacts with ERM proteins54 and with betaII-spectrin169,
but most of its binding partners are still unknown. Transfection of the NF2 gene can reverse
the Ras-induced malignant phenotype and restore contact inhibition188 and inhibits the
growth of NIH 3T3 cells113. The growth-inhibiting activity of merlin seems to depend on the
formation of intramolecular complexes176. The similarities between merlin and the other
ERM proteins suggest that the growth-regulating effects of merlin may be due to alterations in
cytoskeletal function58. Thus it would be a unique type of tumor suppressor. Nevertheless, the
exact tumor suppressor mechanism of the NF2 gene/NF2 protein remains to be settled.
1.3 Meningiomas
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1.3.1 Overview and Epidemiology
Meningiomas are usually benign and slowly growing tumors attached to the dura, but
compression of the brain in a closed space makes them potentially lethal. Complete removal is
the treatment of choice, because meningiomas are usually well demarcated from the adjacent
brain. Most meningiomas cause no symptoms and go unnoticed if not found incidentally on
neuroradiological examination or autopsy149,201. Most patients with a single sporadic
meningioma do not have any genetic predisposition to meningiomas but multiplicity and
young age at presentation suggests NF2.
Meningiomas are estimated to constitute between 20% and 30% of all primary
intracranial tumors, and previous population-based studies mainly in the computed
tomography (CT) or magnetic resonance imaging (MRI) era indicate an overall annual
incidence of 2.0-3.0/100,000 population30,64,66,142,144,166,192. Meningiomas affect
women more often than men in a ratio of approximately 2:1, the difference being greatest in
the older age groups106. However, there is no female predominance among young patients6
nor in the rare anaplastic meningiomas137. Meningiomas are rare in childhood and
adolescence15, and the incidence peaks after the age of 7564. Meningiomas occur in about
50% of NF2 patients123. The tumors are often multiple, occur early in life and there is a
predominance of women even in NF2-associated cases42. Approximately 10 % of all
meningiomas are spinal, and women are markedly overrepresented among these patients143.
Meningioma is the most common primary intraspinal tumor, constituting of about 50% of
these tumors65,143. The annual incidence of spinal meningiomas has been estimated at 0.1-
0.2/100,00065,143.
1.3.2 Neuropathology
Meningiomas are composed of neoplastic meningothelial (arachnoidal) cells.
Approximately 90% of meningiomas are histologically benign, corresponding to grade I
according to the Word Health Organization (WHO) classification of nervous system
tumors86. Atypical (grade II) meningiomas account for 5-15% of all meningiomas, whereas
anaplastic (grade III) forms are rare, accounting for 1-3% of all meningiomas78,107,138.
However, the criteria used to define atypical and anaplastic meningiomas remain
controversial137. Meningiomas vary considerably in histological architecture. The present
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classification follows the WHO system of 199386. Of the various subtypes, meningothelial,
fibrous, and transitional meningiomas are by far the most common107. In a recent histological
study of 110 grade I meningiomas, 53% were meningothelial, 28% transitional, 8% fibrous,
and 11% of other subtypes92. Most subtypes share benign clinical behavior, although some
rare subtypes, such as papillary and clear cell meningiomas, are more likely to recur and
follow a more aggressive clinical course107,138. It has been suggested that most NF2
meningiomas are of the fibrous type109,157 but detailed studies have not been carried out
because few centers can collect sizable series.
Most meningiomas stain for epithelial membrane antigen (EMA) and
vimentin157,200. Immunohistochemical studies of S-100 protein have yielded very variable
results, but S-100 positivity is usually not prominent157. Diagnostic ultrastructural features of
meningiomas include copious intermediate (vimentin) filaments, complex interdigitating cell
processes (particularly in meningothelial variants), and desmosomal intercellular
junctions107.
MIB-1/Ki-67 labeling, which has nowadays in practice superseded other proliferation
markers (PCNA, DNA flow cytometry, BrdU labeling, and AgNOR analysis), has been used
in many studies to assess the proliferation potential of meningiomas (Table
2)1,68,82,83,92,117,130,132,134,139,177. MIB-1 labeling indices (LIs) have shown a highly
significant increase from benign to atypical to anaplastic meningiomas1,83,92,117. MIB-1 LIs
may, however, may vary considerably among anaplastic meningiomas (mean 12%, range, 0.1
to 32.5%, N = 29)1. High proliferation activity may also be focal within tumors, particularly
in regions of high cellularity. High MIB-1 LI (≥ 4.2%) is strongly associated with shortened
recurrence-free survival in patients treated by gross total resection of their meningiomas139.
Multivariate regression analysis also showed MIB-1 LI to be an important independent
prognostic factor for recurrence of meningiomas68. MIB-1 LI appears useful in evaluating
meningiomas with borderline atypia. Proliferation potential of NF2 and sporadic meningiomas
have not been compared previously139, but the more aggressive clinical course of NF2
meningiomas compared to sporadic cases has been noted32.
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Table 2
Previous MIB-1 Studies in Meningiomas.
MIB-1-LIa (number of tumors) in Different Histological Grades
Previous Study G I G II G III
Karamitopoulou et al. 1994 2.47 ± 1.83 (50) - -
Kolles et al. 1995 0.73 ± 1.04 (110) 2.08 ± 1.95 (42) 10.98 ± 10.13 (8)
Nakasu et al. 1995 1.06 ± 0.63  (107) 2.75 ± 1.43 (10) 10.9 ± 6.43 (3)
Maier et al. 1997 3.8 ± 3.1 (15) 7.2 ± 5.8 (29) 14.7 ± 9.8 (35)
Perry et al. 1998 1.5 ± 2.0 (425)b - -
Abramovich et al. 1999 1.0, 0-5.5c   (37) 5.5, 0.1-32.5 (29) 12.0, 0.3-32.5 (24)
Hsu et al. 1999 0.75 ± 0.21 (24) 3.2 ± 0.57 (24) 6.04 ± 1.48 (9)
aMean ± SD
b425 meningiomas with 81% grade I, 15% grade II (atypical), and 4% malignant (brain-invasive)
cMean, Range
1.3.3 Genetics
NF2 gene defects are detected in up to 60% of meningiomas31,97,159,195. The
defects are found almost exclusively in meningiomas with LOH on 22q, indicating that the
NF2 gene acts like a classic tumor suppressor gene in meningiomas. Mutation and/or loss of
NF2 are found in meningiomas of all malignancy grades, suggesting that inactivation of this
gene represents an early genetic event in the pathogenesis of meningiomas159,195. In atypical
and malignant meningiomas, other genes than NF2 seem to be associated with malignant
progression, as suggested by frequent losses on chromosomes 1p, 6q, 9q, 10q, 14q, 17p and
18q84,94,193. Chromosomal gains, most commonly on 20q, 12q, 15q, 1q, 9q and 17q, have
been noted in high-grade meningiomas193. LOH on 1p seems to be the second most common
genetic alteration in meningiomas and is also significantly associated with recurrence-free
survival8,186,193. Of the above chromosomal loci, only the NF2 gene on chromosome 22 has
been implicated as a specific tumor suppressor; the responsible genes on the other frequently
involved chromosomes remain to be identified. The frequency of NF2 mutations differs
among the three most frequent meningioma variants. Fibrous and transitional meningiomas
possess NF2 mutations in 70-80% of cases, whereas only 25% of meningothelial
meningiomas have detectable NF2 mutations195,196. Thus, the latter variant may follow a
genetic pathway independent of the inactivation of NF2 gene.
Sporadic benign meningiomas without LOH on 22q, have shown deletions on 1p and
3p, suggesting that these regions may primarily contribute to meningioma tumorigenesis in a
subset of cases24. Other genes on chromosome 22, for example the ß adaptin (BAM22)140
and MN1 genes98, are also postulated to be involved in the genesis of some meningiomas.
Amplification of protooncogenes CDK4 and/or MDM2 is a rare event in meningiomas193.
1.3.4 Clinical Aspects
Microsurgical resection or removal of symptomatic meningiomas that are accessible
has been the mainstay of the primary treatment of meningiomas. Recurrence is a problem even
in benign (grade I) meningiomas: as many as 19% recur within 20 years after seemingly
complete removal77. The major clinical factor in predicting recurrence is the extent of
resection, which is influenced by the site of occurrence, attachment to intracranial structures,
and the age of the patient. In a recent series from the Mayo Clinic, young age, male sex, less
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than gross total resection, and involvement of the anterior visual pathway were important
variables associated with shortened progression-free survival after primary resection of
meningioma180. Although several histological features are associated with recurrence,
histological anaplasia seems to be the most useful predictor of recurrence. The recurrence rate
is 7-20% in benign meningiomas, 29-38% in atypical meningiomas, and 50-78% in anaplastic
meningiomas78,107,116.
1.4 Schwannomas
1.4.1 Overview and Epidemiology
Schwannoma (previously known as neuroma or neurilemmoma) is a benign, usually
encapsulated tumor composed of neoplastic Schwann cells. Most schwannomas originate
from the vestibular part of the eighth cranial nerve in the cerebello-pontine angle and
approximately one third from the spinal nerve roots156. Peripheral schwannomas mostly
occur in the head and neck regions and extensor aspects of the extremities203 and make up
10-15% of all schwannomas173.
Schwannomas account for an estimated 8-10% of all intracranial tumors in adults, and
their overall annual incidence has been at 0.28-1.27/100,00052,93,142,144,146,192. It is
difficult to estimate the incidence of spinal schwannomas from previous literature since there
are only few studies available, and schwannomas and neurofibromas are usually grouped
together as nerve sheath tumors. Nerve sheath tumors account for 11-25% of all primary
spinal tumors in adults65,143. As schwannomas are estimated to account for about 85% of all
spinal nerve sheath tumors, the annual incidence of spinal schwannomas is approximately 0.1-
0.3/100,00051,65,143,173. The incidence of peripheral nerve and subcutaneous schwannomas
in a population is unknown. Schwannomas occur approximately equally in both sexes at any
ages, but the peak incidence is in the fourth to sixth decades of life30,52,156,203.
1.4.2 Neuropathology
Schwannomas (WHO grade I) are composed of interlacing bundles of bipolar spindle-
shaped Schwann cells with elongated nuclei. The growth pattern consists of Antoni A areas,
represented by closely packed tumor cells, and Antoni B areas, where tumor cells are loosely
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arranged. Sometimes the cells are arranged in a palisade fashion with their nuclei aligned,
occasionally forming rounded Verocay bodies. Mitoses are sparse. Vasculature is typically
thick-walled and hyalinized, and dilated blood vessels surrounded by or invested with
hemorrhage are commonly observed.
Schwannoma cells show strong and diffuse expression of the calcium-binding protein
S-100, a feature which has been widely used to identify Schwann cells both in situ and in
culture194,203. Schwannomas often express Leu-7 and are variably stained by antibodies
against glial fibrillary acid protein (GFAP)156. The most prominent electron microscopic
feature of Schwann cells is a well-developed basal lamina41.
Cellular schwannoma (WHO grade I) is a hypercellular variant of schwannoma
composed predominantly of Antoni A tissue and devoid of Verocay bodies202. The most
common location of cellular schwannoma is the paravertebral region of the retroperitoneum,
pelvis, and mediastinum198. Cellularity and mitotic activity are higher than in classic
schwannomas202. Cellular schwannoma does not differ from classic schwannoma in clinical
picture, but its fascicular growth of cells, occasional nuclear hyperchromasia and atypia, and
often readily apparent mitotic activity may mislead to diagnosis of malignant peripheral nerve
sheath tumor (MPNST)25,174,198. Therefore, correct histological diagnosis is of utmost
importance.
MPNST (WHO grade II-IV, previously known as malignant schwannoma,
neurofibrosarcoma, or neurosarcoma) is a rare malignant tumor arising from peripheral
nervous tissue203. Almost two-thirds originate from neurofibromas, often of the plexiform
type, in the setting of NF1168. Roughly 10% develop at the site of prior irradiation36.
MPNSTs have varied histology. The majority show a fibrosarcoma-like fasciculated growth of
tightly packed, hyperchromatic spindle cells with abundant cytoplasm203. Generally,
MPNSTs are highly aggressive tumors with poor prognosis. Overall 5 -and 10-year survival
rates are 34% and 23%36.
Few studies have assessed the proliferation potential of sporadic schwannomas by
means of MIB-1 or Ki-67 labeling19,28,101,108,177. In two previous studies, MIB-1 or Ki-
67 staining was used to evaluate the growth potential of sporadic vestibular
schwannomas.28,101. Charabi et al. determined the proliferation potential of 21 sporadic
vestibular schwannomas, and found that tumors with high MIB-1 values had a shorter duration
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of preoperative symptoms28. Lesser et al. obtained Ki-67-LIs of 0.36 to 3.15 (mean 1.45) in
eight apparently sporadic vestibular schwannomas101. The tumor with the highest Ki-67-LI
(3.15) invaded the facial nerve and its diameter had increased by 3 mm in three months. The
proliferation rates of sporadic and NF2 schwannomas has not been compared previously.
NF2 schwannomas differ from sporadic schwannomas in many ways. NF2
schwannomas present at an earlier age and are often multiple. NF2 schwannomas may show a
lobular, "grape-like" growth pattern on both gross and microscopic examination while such
patterns are extremely uncommon in sporadic schwannomas178. Verocay bodies and foci of
high cellularity are also more commonly observed in NF2 schwannomas than in sporadic
cases178. Sobel et al. suggested that NF2 tumors feature higher Schwann cell proliferation,
whereas ongoing thrombosis, hemorrhage, and angiogenesis are intrinsic to sporadic vestibular
schwannoma178. Vestibular schwannomas in NF2 patients often contain embedded eighth
nerve fibers, whereas embedded axons are less common in sporadic schwannomas61,79.
Consequently, preservation of the continuity and function of the facial and cochlear nerves
during surgery has been more difficult in NF213,14,20,165. In NF2, multiple schwannomatous
tumourlets may develop along individual peripheral nerves, particularly on spinal roots, whereas
such lesions have not been described in sporadic patients182. These observations indicate
distinct biological differences between sporadic and NF2 schwannomas.
1.4.3 Genetics
Chromosome 22 monosomy in schwannomas was observed by Mark already in
1972120. In subsequent cytogenetic studies, chromosome 22 monosomy was detected as a
consistent chromosomal change in approximately 50% of schwannomas7,29,184. These
karyotyping analyses have reported random genetic aberrations other than those involving
chromosome 22, for example on chromosomes 10, 12, 14, 15, 17, 18 and 19 (losses) and on
chromosomes 5, 7 and 20 (gains)7,184. Seizinger et al. found LOH on 22q in 44%
schwannomas but not on the other chromosomal regions (chromosomes 1, 4, 10, 11, 12, 13,
14, 17, 18, 19, and 21) studied170. LOH in the regions of known tumor suppressor genes
(VHL, APC, p53, and NF1) on 3p, 5q, 17p and 17q was not detected in schwannomas170.
After the cloning of the NF2 gene in 1993, subsequent studies detected NF2 gene mutations in
numerous schwannomas12,72,74,75,97,128,190, confirming the prediction that this tumor
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suppressor is integral to schwannoma formation. To date, inactivating NF2 mutations have
been detected in up to 60% of both sporadic and NF2 schwannomas74. However,
approximately 40% of schwannomas have no detectable NF2 gene mutation, suggesting
possible superimposed secondary or alternative genetic abnormalities in these schwannomas.
Losses on 1p100 and gains on 11q167 have been detected in a few schwannomas but no single
consistent genetic alteration associated with schwannomas, other than a loss on 22q has been
found to date, and such changes have not been systematically searched previously.
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2 AIMS OF THE STUDY
This study was designed to answer the following questions:
I Do NF2 schwannomas have a higher proliferation potential than do sporadic
schwannomas?
II Are there histological differences between NF2 and sporadic meningiomas, and do
NF2 meningiomas have a higher proliferation potential than do sporadic
meningiomas?
III Do schwannomas have additional genetic aberrations besides the partial loss of
chromosome 22? Are there differences in genetic aberrations between NF2 and
sporadic schwannomas?
IV What is the proportion of NF2, meningiomatosis and schwannomatosis among
sporadic cases in a population?
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3 PATIENTS, TUMORS, AND METHODS
3.1 Patients and Tumors for Proliferation and Comparative Genomic Hybridization
Analyses (I-III)
3.1.1 Neurofibromatosis 2 Patients and Tumors
From 1975 to 1992, a total of 26 vestibular schwannomas were removed from 19 NF2
patients at the Department of Neurosurgery, Helsinki University Central Hospital (HUCH),
Helsinki. These patients also had three spinal and 10 subcutaneous schwannomas, and these
tumors were included in the study. In addition, six vestibular schwannomas from three NF2
patients operated on during the same time period at the Department of Neurosurgery, Oulu
University Central Hospital, Oulu, were included. Of the original 45 schwannomas, 38 (26
vestibular, two spinal, and 10 subcutaneous) from 22 NF2 patients were available for
histological re-examination and proliferation analysis. Twelve of these 38 schwannomas were
randomly selected for the comparative genomic hybridization (CGH) analysis.
From 1975 to 1994, a total of 10 operated meningiomas were removed from 21 NF2
patients at the Department of Neurosurgery, HUCH. To increase the total number of NF2
meningiomas and ensure a valid comparison between NF2 and sporadic meningiomas, a
collaborative study was conducted with the Department of Neurosurgery, Krankenhaus
Nordstadt, Hannover, Germany. Twenty-one NF2 patients had 33 meningiomas removed in a
consecutive series of 116 NF2 patients operated on in 1982-1996 at the Krankenhaus
Nordstadt, Hannover, Germany. Of the combined 43 meningiomas, 35 (32 intracranial and
three spinal) from 23 NF2 patients were available for histological re-examination.
All 42 patients fulfilled the established criteria of NF257. Twelve of the Finnish NF2
patients (from four different families) and six German patients (from six different families) had a
familial form of NF2. Ten of the Finnish and 15 of the German patients suffered from a severe
NF2 (Wishart type) with multiple intracranial and spinal schwannomas and/or meningiomas.
3.1.2 Sporadic Patients and Tumors
Twenty-seven unilateral tumors were randomly selected from a consecutive series of 332
sporadic vestibular schwannomas operated on between 1979 and 1992 at the Department of
Neurosurgery, HUCH. In addition, 34 age-matched sporadic controls, including 11 from the
above group of 27 unilateral tumors, were selected for 17 NF2 patients, because the age
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difference between the sporadic and NF2 patients might be a reflected in the proliferation
activity of vestibular schwannomas. Age-matching was not possible for the two youngest NF2
patient. In addition, 20 randomly selected benign spinal schwannomas, all six available spinal
cellular schwannomas, and four MPNSTs in a consecutive series of 144 spinal nerve root tumors
operated on in Helsinki between 1974 and 1992173 were studied. One patient with spinal
MPNST had NF2, as BVSs were observed at autopsy. The other sporadic schwannoma patients
did not have any other clinical signs of NF2 or family history of NF2-related tumors. Three
sporadic schwannomas (two cellular and one MPNST) were excluded because of small and/or
necrotic tissue samples. Twelve of the 27 sporadic vestibular schwannomas and one spinal
cellular schwannoma were randomly selected for CGH analysis.
Thirty intracranial sporadic meningiomas were obtained from a population-based
consecutive series of 992 non-NF2 patients operated on for a primary intracranial or spinal
meningioma (hemangiopericytomas excluded) at the Department of Neurosurgery, HUCH, in
1981-1996. These 30 meningiomas from 30 patients were sex-matched with the 23 NF2
patients and age-matched (age at operation) with the 35 NF2 meningiomas. No signs of NF2
in these 30 patients had appeared until June, 1996 (mean follow-up time 3.4 years, range from
two months to 14 years), and none were found in the re-examination of the preoperative and
follow-up CT or MRI scans. Maximum tumor diameter and the maximum diameter
perpendicular to this were measured from preoperative CT or MRI scans, available from 28
NF2 meningiomas and 28 sporadic meningiomas.
3.2 Immunohistochemistry and Proliferation Analysis (I, II)
All NF2 and sporadic schwannomas were re-evaluated by a neuropathologist (H.
Haapasalo). Histological typing, grading (I-III), and comparison of the sporadic and NF2
meningioma samples stained with hematoxylin and eosin was performed by a
neuropathologist (M. Haltia) applying the criteria of the 1993 WHO classification of brain
tumors86. The following morphological parameters were visually estimated and graded from
0 to 3: increased cellularity, nuclear pleomorphism, mitotic figures and focal necroses.
The original tissue samples had been fixed in phosphate-buffered formaldehyde and
embedded in paraffin. New representative sections (4 to 5 µm in thickness) were dewaxed in
xylene and rehydrated in graded series of ethanol to water. Ki-67 nuclear antigen retrieval was
performed in citrate buffer (pH 6.0) by the microwave oven processing technique26. The
sections were treated twice for 7 min at 850 W in a microwave oven, after which the sections
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were allowed to cool in buffer for 30 min. For Ki-67 antigen immunostaining, mouse
monoclonal antibody (mAb) MIB-1 (IgG1, Immunotech S.A., Marseille, France) was used at a
1:40 dilution. The sections were incubated at +4ºC overnight, and the primary antibody was
detected using the streptavidin-biotin technique (Zymed Laboratories Inc., CA). Counterstaining
was carried out with 0.4% ethyl green in acetate buffer for 15 min.
Proliferating cell nuclear antigen (PCNA) retrieval was done by incubating the sections
in 1:3 diluted TUF (Target Unmasking Fluid, Sanbio, Uden, The Netherlands) 90°C for 10 min
and thereafter allowing the sections to cool in the unmasking fluid for 15 min. After washing in
0.1 M phosphate-buffered (pH 7.3) saline (PBS), the sections were incubated with a 1:200
dilution of mAb 19A2 (IgM, Coulter Immunology, Hialeah, FL) at +4ºC overnight. The bound
antibodies were revealed by the streptavidin-biotin immunoperoxidase technique using
diaminobenzidine (0.5 mg/ml) as chromogen. The sections were counterstained with 0.2% ethyl
green in 0.1 M buffered acetate for 30 min. Proliferative normal tissues (gut, skin) were used as
positive controls.
LIs were calculated using a computer-assisted image analysis system (CAS-200®
Software, Becton Dickinson, CA). This microscope-based system is equipped with two cameras
that digitize the image of immunopositive (brown) and immunonegative areas (green) in nuclei
for computer analysis. The staining results were scored as percentages of MIB-1-
immonupositive and PCNA-immunopositive tumor cell nuclei (MIB-1-LI and PCNA-LI).
Twenty microscopic fields (x400) with the highest numbers of immunopositive nuclei were
selected for the analysis. Endothelial cells, necrotic and hemorrhagic areas, and section borders
were omitted.
3.3 Comparative Genomic Hybridization (III)
Hematoxylin and eosin-stained diagnostic sections (5 µm) from paraffin-embedded,
formalin-fixed schwannoma samples were used for selecting the histologically most
representative tumor areas from which genomic DNA was extracted using the QIAmp Tissue
Kit (Qiagen GmbH, Hilden, Germany).
CGH was performed as described by Sallinen et al.164. Normal reference DNAs were
labeled by nick translation with Texas Red-dUTP (DuPont, Boston, MA) and tumor DNAs
with fluorescein isothiocyanate (FITC)-dUTP (DuPont). 600 ng of both tumor DNA and
normal reference DNA, as well as 10 µg of unlabeled human Cot-1 DNA (Life Technologies,
Gaithersburg, MD) were hybridized onto normal metaphase chromosomes (Vysis Inc.,
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Downers Grove, IL). The hybridization was performed in a moist chamber at 37°C for 48
hours. For each batch of hybridization, two control experiments were performed. These
consisted of hybridizations of normal male DNA against normal female DNA and of DNA
from the previously characterized breast cancer cell line, MCF-7, against normal female DNA.
The hybridization results were visualized using an epifluorescence microscope (Olympus
BX50, Tokyo, Japan) equipped with a cooled charge coupled device camera (Cohu 4910,
Cohu Inc., San Diego, CA) and analyzed using the Quips CGH analysis program (Resource of
Molecular Cytogenetics, Lawrence Berkeley National Laboratory, Berkeley, CA) based on the
Sciliamge program (TNO, Delft, The Netherlands). Chromosomal regions for which the mean
green-to-red ratio fell below the value of 0.80 - 1 SD (standard deviation of the ratio) were
considered lost, whereas mean ratios exceeding the value of 1.2 + 1 SD were considered to
indicate gains. P arms of acrocentric chromosomes, heterochromatic regions, chromosomal
telomeres and chromosomes Y were excluded from the analysis.
3.4 Loss of Heterozygosity and Fluorescence in Situ Hybridization Analyses (III)
In selective schwannoma cases, the CGH findings were further analyzed by LOH and
fluorescence in situ hybridization (FISH) techniques using standard methods. LOH was done
using the polymorphic microsatellite DNA markers (Pharmacia, Uppsala, Sweden) mapping
to 13q14-31: D13S144, D13S146, D13S318, D13S152, D13S800, D13S156, D13S269,
D13S162, D13S789, D13S1306, D13S160, D13S125 (The Genome DataBase and Klockars et
al. 199688) and with an NF2 intragenic marker to 22q12: CA318. The tumor DNA was
extracted from paraffin embedded microdissected tissue samples with standard methods using
phenol/chloroform purification and ethanol precipitation. Amplification of the microsatellite
loci was performed by "touchdown" PCR35 using fluorochrome (Cy5) labeled primers. The
PCR products were separated by gel electrophoresis (ALFexpress, Pharmacia) and analyzed
by the AllelLinks software (Pharmacia). LOH was scored when major reduction or total loss
of one allele was observed in the tumor DNA compared to the normal tissue sample.
Interphase nuclei were extracted from paraffin blocks for FISH experiments according
to published methods70. Three PAC probes, one (35j3) specific for human chromosome
13q22 and two specific for human chromosome 19p13 (27A14, 235B21) were screened from
PAC library (Dr. P. de Jong, Roswell Memorial Institute, Buffalo, NY). Probes were labeled
with biotin 11-dUTP (Sigma Chemicals Co, St. Louis, MO) or digoxigenin 11-dUTP
(Boehringer Mannheim GmbH, Germany) by nick translation according to standard protocols.
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FISH analysis was carried out in 50% formamide, 10% dextran sulfate in 2xSSC, and the
signals were detected by conventional methods as described earlier104,141. The slides were
counterstained with DAPI (4'-6'-diamino-2-phenylindole; 5 µg/ml, Sigma) in antifading
reagent (Vectachield, Vector Laboratories, Inc., Burlingame, CA). A multicolor image
analysis was used for acquisition, display and quantification of hybridization signals of
interphase nuclei63.
3.5 Population-Based Analysis of Sporadic and Neurofibromatosis 2-Associated
Meningiomas and Schwannomas (IV)
3.5.1 Source Population, Patients, and Tumors (IV)
The source population comprised the catchment area of HUCH, consisting of 100
municipalities around the City of Helsinki in southern Finland. The mean population of the
catchment area was 1,557,200 (743,600 men and 813,600 women) during the 11 years of
study from January 1, 1985 to December 31, 1995. The catchment area was served by the
Department of Neurosurgery (HUCH) as the unit with population responsibility.
The patient material consisted of all patients diagnosed with primary histologically
verified intracranial, spinal, or peripheral schwannoma(s) or meningioma(s), who resided in
the HUCH catchment area at time of diagnosis. Patients were identified from the following
sources: (1) operation list and files of the Department of Neurosurgery, HUCH, (2) discharge
and outpatient files of the HUCH, (3) files of the Department of Pathology, University of
Helsinki, and (4) files of the Finnish Cancer Registry (FCR). All available clinical data,
including patients' medical records and radiography (CT and MRI scans) and autopsy data,
were reviewed to record the occurrence of multiple schwannomas and meningiomas or other
features suggestive of NF2. Meningiomas and schwannomas had been classified
histologically, according to the WHO Classification of 1979206 or 199386 by a consulting
neuropathologist, and the histological diagnoses were not re-evaluated.
A total of 1,318 patients with primary meningioma or schwannoma had been
diagnosed in the HUCH catchment are in 1985-1995. The total number of patients analyzed
was 1,278, as 40 patients (3.0%) were excluded for absence of case records (N = 11) or
histological verification (N = 29). The latter cases had been diagnosed either by CT (N = 24)
or MRI (N = 5) scan. The histological diagnoses were based on tissue samples obtained at
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surgery (N = 1,178) or autopsy (N = 100). All the 100 autopsied cases (69 women and 31
men; median age of 77 years; range 21 to 93 years) had intracranial meningioma, including six
patients with multiple meningiomas. Of these 100 cases, the meningiomas of 86 patients were
first detected at autopsy while the meningiomas of 14 patients were already known (CT or
MRI scan) but had not been operated on.
3.5.2 Population Register Center and Finnish Cancer Registry (IV)
The Population Register Center (PRC), founded in 1969, is a government agency
maintaining vital records on all Finnish citizens and on foreigners residing permanently in
Finland. In 1973, the family relation records were transferred to PRC from parish registries.
Information about parents, which is needed to identify siblings, appears in the PRC database
only if the person has resided with his/her parents in 1973 or thereafter. The information about
family relations other than a person's own children is, therefore, incomplete for persons older
than 45 years.
The Finnish Cancer Registry (FCR) was founded in 1952 and covers the whole
population of Finland. Physicians, hospitals, and pathologists are obliged to report all new
cancer cases (benign and malignant intracranial and spinal tumors included) to FCR, which
also receives information from all death certificates that mention cancer. Registration has been
reliable and virtually complete: over 99% of the 63,722 solid tumors diagnosed in Finland
between 1985 and 1988 were recorded at FCR187. All diagnostic code entries are checked by
a physician. There is no obligation to report benign cutaneous or peripheral nerve tumors to
FCR.
A total of 4,530 relatives of the 1,278 patients of the present study were found in the
PRC database, and FCR files were searched to find all neoplasms diagnosed in these 4,530
relatives.
3.5.3 Pedigree Analysis (IV)
Detailed pedigrees containing all first- and second-degree relatives were constructed
for the following four groups of 79 patients on the basis of parish records: 17 NF2 patients, 40
patients with two or more schwannomas or meningiomas, five patients with relative(s) with
histologically verified schwannoma(s) or meningioma(s), and 17 patients under 25 years of
age at the time of diagnosis.
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3.6 Statistical Methods (I-IV)
Median, or mean, and range were used to describe distributions, and Mann-Whitney or
chi-squared-tests to compare groups. StatView IV (Abacus Concepts, Berkeley, CA) or
SYSTAT (SYSTAT Inc., CA) software was used to compare labeling indices between
different meningioma and schwannoma groups by the Mann-Whitney test, to correlate
labeling indices with patients' age and tumor diameter by the Pearson correlation coefficient
and linear regression analysis, and to compare morphological parameters and gender
distribution between NF2 and sporadic meningiomas by the chi-squared-test.
An annual age-adjusted incidence rates (per 100,000 persons) were calculated by the
direct method153 using the World Standard Population as a standard. In the direct method, the
number in the standard population in each age group is multiplied by the incidence in each
group of the observed population in order to obtain the number of cases that would occur in
the standard population. Then, the expected numbers thus obtained are added together and
divided by the total number in the standard population to give the incidence rate standardized
for age.
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4 RESULTS AND DISCUSSION
4.1 Proliferation Potential of Sporadic and Neurofibromatosis 2-Associated
Schwannomas and Meningiomas and Histological Features in NF2-Associated
Meningiomas (I,II)
MIB-1 (Table 3) and PCNA LIs were significantly higher in vestibular schwannomas in
NF2 patients than in sporadic cases (MIB-1-LI: 1.72 vs. 0.95, p <0.01; PCNA-LI: 1.40 vs. 0.81,
p <0.01). No correlation was found between patient's age or sex and MIB-1-LI within the NF2
group, nor within the sporadic group. Vestibular schwannomas from NF2 patients also had
significantly higher MIB-LIs than those from age-matched controls (1.72 vs. 1.05, p <0.01).
When the two youngest NF2 patients, for whom age-matching was not possible, were excluded
from the analysis, the difference in MIB-1 LIs was still statistically significant (1.67 vs. 1.05, p
<0.01). The MIB-1-LIs of 108 benign schwannomas were significantly lower than those of four
cellular schwannomas (p = 0.02) or two MPNSTs (p <0.01) (Table 3).
Table 3
MIB-1 LIs of Schwannomas from NF2 Patients and from Sporadic Cases.
Cases Mean Age (range) a
Sex F/M
MIB1-LI
(mean ± SD)
VS in NF2
(N = 26)
33 (7-57)
10/9
1.72 ± 0.93b
Sporadic VS
(N = 27)
52 (23-67)
18/9
0.95 ± 0.57
Age-Matched Sporadic VS
(N = 34)
38 (16-58)
17/17
1.05 ± 0.59
Benign Spinal Schwannomas
(N = 20)
47 (25-75)
8/12
1.93 ± 1.28
Cellular Spinal Schwannomas
(N = 4)
42 (28-51)
2/2
2.23, 2.27, 2.77, 8.73c
MPNST
(N = 2)
18 and 24
1/1
8.80, 34.78c
aMean age and range in years
bp <0.01 compared with sporadic and age-matched sporadic VS
cAll MIB-1 LIs are shown
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MIB-1-LIs (Table 4) were significantly higher in the 35 meningiomas from 23 NF2
patients than in the 30 sporadic meningiomas from the 30 age- and sex-matched non-NF2
cases (mean MIB-1-LI: 2.50 vs. 1.75, p = 0.01). MIB-1-LI did not correlate with patient’s age
at operation or sex. The 29 symptomatic NF2 meningiomas had higher indices than did the six
incidental NF2 meningiomas (mean MIB-1-LI: 2.84 vs. 1.40, p = 0.02). As expected, the eight
atypical meningiomas showed higher MIB-1-LIs than did the 57 benign ones (mean MIB-1-
LI: 3.51 vs. 2.02) but the difference was not statistically significant (p = 0.06).
Meningothelial, fibrous, and transitional subtypes occurred equally among the NF2
meningiomas and the sporadic control meningiomas (Table 5). When graded according to
histological anaplasia, the 35 NF2 meningiomas consisted of 30 benign (WHO grade I) and
five atypical (WHO grade II) tumors, and the 30 sporadic meningiomas consisted of 27 benign
and three atypical tumors. NF2 meningiomas exhibited more mitotic figures (sum of grading
points: 24 vs. 7, p <0.01) and nuclear pleomorphism (32 vs. 14, p <0.01) than did sporadic
Table 4
Comparison of MIB-1-LIs in NF2 Meningiomas and Sporadic Meningiomasa.
WHO Grade NF2
(35 tumors)
Matched Sporadicb
(30 tumors)
Other Sporadicc
(330 tumors)
All 2.50 ± 1.44 1.75 ± 1.21d 1.66 ± 1.83
I Benign 2.26 ± 1.27 1.74 ± 1.28 1.15 ± 0.99
II Atypical 2.04, 2.43, 3.52,
6.84, 7.61e
1.25, 1.44, 2.97e 2.21 ± 1.85
III Anaplastic - - 10.95 ± 9.12
aAll values represent mean LIs ± SD
bPatients were matched by age and gender to NF2 patients with meningiomas
cData on other sporadic meningiomas were collected from Karamitopoulou et al. 199482,
Kolles et al. 199592, and Nakasu et al. 1995132
dp = 0.01 compared with all NF2 meningiomas
eAll MIB-1-LIs are shown
- = not applicable
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meningiomas. No other specific histological features distinguishing NF2 meningiomas from
the sporadic tumors were observed.
4.1.1 Difference in Proliferation Potential (I, II)
Although the NF2 gene is integral to the pathogenesis of both NF2 and sporadic
schwannomas and meningiomas, a clear difference in proliferation activity was found between
NF2 and sporadic tumors. Age does not explain the higher MIB-1 LIs in NF2 tumors, as the
significantly higher proliferation potential was maintained on the age-matched analysis. In
addition, there was no correlation between patient's age and MIB-1-LI within either group. The
Table 5
Comparison of Patient Age and Gender and Histological Types in NF2-associated and
Sporadic Meningiomas.
Patient Characteristics
and Tumor WHO Grade
NF2 Matched Sporadica Other Sporadicb
N of Patients
Female/Male-Ratio
Mean Age (range)c
23
1.6 (14/9)
29 (16-54)
30
1.5 (18/12)
31 (15-53)
330
2.2d
58 ± 13e
N of Meningiomas
Grade I (benign)
Fibrous
Meningothelial
Transitional
Other
Grade II (atypical)
Grade III (anaplastic)
35
30 (86%)
9 (30%)
5 (17%)
16 (53%)
-
5 (14%)
-
30
27 (90%)
9 (33%)
5 (19%)
13 (48%)
-
3 (10%)
-
330
267 (81%)f
8%
53%
28%
11%
52 (16%)
11 (3%)
aPatients were matched by age and gender to NF2 patients with meningiomas.
bData on other sporadic meningiomas were collected from Karamitopoulou et al. 199482,
Kolles et al. 199592, and Nakasu et al. 1995132
cAge at time of tumor removal
dFemale/male ratio from Kolles et al. 199592, and Nakasu et al. 1995132
eMean age ± standard deviation from Nakasu et al. 1995132
fDistribution of subtypes of benign meningiomas from Kolles et al. 199592
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higher proliferation of NF2 tumors may partly explain why they manifest at a younger age than
do sporadic tumors.
There are at least three explanations for the higher proliferation of NF2 tumors. Firstly,
the surrounding tissue may be different in NF2. Based on the functions of homologous proteins,
the NF2 gene product merlin (schwannomin) has been postulated to act as a linker between
cytoskeletal and cell membrane structures. A defective NF2 gene may reduce the activity of
merlin (schwannomin) at the interface between the plasma membrane and the cytoskeleton and
cause dysfunction in adhesion molecules which are essential to normal Schwann cell
development and regeneration39,50,102. This dysfunction could cause loss of cell-cell contact
growth inhibition and result in more aggressive tumor growth patterns in NF2 patients, whose
adjacent tissues express only one functional NF2 gene. Secondly, the difference in proliferation
could reflect variation in NF2 gene mutations in sporadic and NF2 tumors. In schwannomas,
mutational analysis of several series indicates that LOH on chromosome 22, causing inactivation
of the entire NF2 gene, is much more common in sporadic (68/165, 41%) than in NF2 (4/24,
17%) vestibular schwannomas11,12,72,75,97,162. LOH could lead to a less aggressive
phenotype with slowly-growing schwannomas compared with mutations producing a truncated
NF2 gene product. This is supported by the finding that large deletions encompassing the whole
NF2 gene have been found to be associated with mild NF2 phenotypes17,205, whereas
mutations that produce a truncated protein have often been found in severely affected cases158.
Furthermore, one study suggested that the frequency, type, and distribution of NF2 gene
mutations differ between sporadic and NF2 schwannomas197, but this finding was not
confirmed in a subsequent study74. No correlations were found between the type of NF2 gene
mutation and either the PCNA labeling index or the clinical growth rate in a series of 94
sporadic vestibular schwannomas71, suggesting that NF2 gene inactivation is not the only
determinant of tumor behavior in schwannomas. However, no comparison between NF2
schwannomas and sporadic tumors was made and PCNA labeling index has been found to be a
more variable proliferation marker than MIB-1127,163. Thirdly, other genes could be altered in
sporadic schwannomas and meningiomas, although consistent aberrations in other
chromosomes than 22 were not detected in schwannomas in the present study (III). NF2 gene
defects are detected in up to 60% of meningiomas, suggesting that another tumor suppressor
gene or genes in chromosome 22q may play a role in the pathogenesis of sporadic
meningiomas. One such candidate is BAM22 on chromosome 22, a member of the ß-adaptin
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gene family37,140, which may be inactivated in some sporadic meningiomas and might be
associated with a slow proliferation rate. In addition, sporadic meningiomas without LOH on
22q, have shown deletions on 1p and 3p, indicating that these regions may contribute to
meningioma tumorigenesis in a subset of cases24. Moreover, a recent study found that some
sporadic schwannomas harbor a genetic alteration near the NF2 locus without detectable
mutations in the NF2 gene itself, suggesting that chromosome 22 has a potential modifier
gene that might be involved in the development of some schwannomas22.
The higher proliferation rate of NF2 schwannomas compared with sporadic cases was
reported independently by Aguiar et al.2 and ourselves (I). The results of Aguiar et al. 2 are
essentially in line with the present study. Recently, the high proliferation rate of NF2
schwannomas has been shown in Schwann cell cultures152. Interestingly, there are differences
in electrophysiological parameters between NF2 and sporadic schwannoma cells. NF2 cells
were found to have a significantly higher membrane potential and larger non-inactivating K+
outward current, compared with sporadic schwannoma cells80. Normally, the proliferation of
Schwann cells is suppressed by inhibition of voltage-dependent K+ currents80. Furthermore,
the expression of plasminogen activator inhibitor 1 (PAI-1) is reduced in NF2 schwannomas
compared with sporadic tumors, suggesting increased total proteolytic activity in NF2
schwannomas, which may be related to the more invasive and aggressive behavior of these
tumors (Sirén et. al., unpublished data). These observations further support the view, that
there are distinct biological differences between sporadic and NF2 schwannomas.
4.1.2 Histological Findings in NF2-Associated Meningiomas (II)
One aim of the present study was to identify histological features specific to NF2
meningiomas, as such have been found in schwannomas. However, the study failed to find
specific histological features distinguishing NF2 meningiomas from the sporadic tumors,
albeit signs of anaplasia were more frequent in NF2 meningiomas, in line with the MIB-1
findings. As in schwannomas, NF2 meningiomas had a significantly higher proliferation
potential compared with sporadic matched controls. Among NF2 meningiomas, the fibrous
variant was clearly overrepresented (30%) and the meningothelial one was uncommon (17%),
compared with previously published data on sporadic meningiomas (Table 5)92. Surprisingly,
fibrous meningiomas comprised 33% of our young age-matched control group, although the
pure fibrous subtype seems to be rare in unselected sporadic meningiomas76,151; this
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difference in meningioma subtypes may reflect age-related differences rather than NF2-related
differences.
4.3 Genetic Aberrations in Sporadic and Neurofibromatosis 2-Associated Schwannomas
(III)
CGH analysis detected genomic abnormalities in 15 of 25 schwannomas (60%). A
total of 26 genetic aberrations were detected, losses (19/26) being more common than gains
(7/26). The most common alteration was loss on 22q, which was found in 8/25 (32%) of
schwannomas (Table 6). Three cases suggested loss of 13q. Gain of 17 or 19 was detected in
two schwannomas.
The loss on 22q was somewhat more common in NF2 tumors than in sporadic
schwannomas: 5/12 (42%) vs. 3/13 (23%). A total of 14 genetic aberrations were detected in
the 12 NF2-associated schwannomas (1.2 aberrations per schwannoma), whereas there were
17 aberrations in the 13 sporadic schwannomas (1.3 aberrations per schwannoma). No
correlation between MIB-1 indices of schwannomas and the number of genetic aberrations was
revealed (r = 0.02, Pearson correlation coefficient).
The genomic abnormalities of chromosome 22 (-22q, 8/25 schwannomas), chromosome
13 (-13q, 3/25), and chromosome 19 (+19, 2/25), suggested by the CGH analysis, were further
evaluated by independent methods. The losses on 22q were confirmed by LOH in two
schwannomas. In contrast, the three losses on 13q could not be confirmed by LOH using 12
microsatellite markers spanning the region 13q14-31 (data not shown). Further, the gains on
chromosome 19 were not confirmed by FISH analysis (data not shown). Thus, loss of 22q was
concluded to be the only consistent chromosomal aberration in schwannomas.
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Table 6
Characteristics of 8 NF2 and 13 Sporadic Patients with 25 Schwannomas Analyzed by Comparative Genomic Hybridization (CGH).
Case
Numbera
Ageb/Sex NF2
Familiesc
Location Number of
Chromosomal
Aberrations
(Losses/Gains)
Chromosomal
Aberrations
MIB-1
Indicesd
Course of the Disease
1 NF2 18/M Non-
Familial
Vestibular 2 (2/0) -4q, -6q21-q22 1.05 Severe: BVSs, meningiomatosis, cervical
ependymoma, multiple peripheral
schwannomas
2 NF2 17/F Non-
Familial
Vestibular 0 (0/0) None 1.73 Severe: BVSs, multiple spinal and peripheral
schwannomas
3 NF2 39/F A Vestibular 1 (1/0) -22qcen-q12 1.10 Severe: BVSs, meningiomatosis
4 NF2 14/F A A Vestibular sin
B Vestibular dx
C Subcutaneous
D Subcutaneous
E Subcutaneous
0 (0/0)
1 (1/0)
1 (1/0)
1 (1/0)
0 (0/0)
None
-22qcen-q12
None
None
None
1.96
2.18
NA
NA
NA
Severe: BVSs, meningiomatosis, multiple
spinal and peripheral schwannomas
5 NF2 37/M B Vestibular 1 (1/0) -22q12-qter 2.98 Mild: BVSs
6 NF2 44/F C Vestibular 0 (0) No 3.22 Mild: BVSs
7 NF2 47/M C Vestibular 2 (1/1) +19, -22qcen-q12 1.76 Mild: BVSs
8 NF2 57/F D Vestibular 5 (3/2) +1p36-p32, -13q21-q31,
+17q, -22, -Xq21-qter
0.96 Mild: BVSs, meningiomatosis
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9 Sporadic 51/M Spinal (cellular
schwannoma)
3 (1/2) -13q22, +17, +X 2.77
10 Sporadic 23/F Vestibular 1 (0/1) None 0.63
11 Sporadic 46/F Vestibular 1 (1/0) -Xp11-qter 0.79
12 Sporadic 50/F Vestibular 1 (1/0) -21q21 0.52
13 Sporadic 62/F Vestibular 2 (2/0) -16q, -22q12-qter 0.80
14 Sporadic 60/F Vestibular 0 (0/0) None 0.75
15 Sporadic 60/F Vestibular 3 (1/2) -20q12-cen, +X 1.31
16 Sporadic 42/M Vestibular 2 (1/1) -22q 0
17 Sporadic 57/F Vestibular 0 (0/0) None 0.64
18 Sporadic 50/F Vestibular 1 (1/0) -22q 2.42
19 Sporadic 51/F Vestibular 1 (1/0) +19 1.27
20 Sporadic 46/M Vestibular 3 (3/0) -13q21-q31, -X 1.69
21 Sporadic 65/F Vestibular 0 (0/0) None 0.88
aNF2 or sporadic patient
bAge at the time of the surgery
cFamilial (A, B, C, D = NF2 families) or non-familial NF2 patient
dMIB-1 indices from a previously published series (I)
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Loss of the chromosome 22 harboring the NF2 gene has been the only consistent
genomic alteration found in schwannomas to date. However, previous studies have mainly
concentrated on chromosome 22, and no genome wide screenings have been done in
schwannomas. In addition, previous cytogenetic and LOH studies have their limitations in
identifying regions of the genome. Solid tumor cytogenetics requires growing of tumor cells in
vitro, which in theory may introduce changes not present in vivo. LOH studies are also not
ideal in that they only detect deletions, and usually only a few loci per chromosome are tested.
CGH offers advantages over these methods since it does not involve in vitro culture of tumor
tissue and allows rapid detection and localization of gains and losses across the entire genome.
CGH also has limitations: it does not detect balanced structural rearrangements, and it has
limited sensitivity, particularly in detecting small deletions (<5-10 Mb)48. CGH analysis may,
therefore, have missed some small 22q deletions in the present series. The limited sensitivity
of CGH may also partly explain why no differences in genetic alterations were detected
between sporadic and NF2 schwannomas.
One CGH study has been published on gastric schwannomas which resemble ordinary
schwannomas histologically, but are extremely rare167. One of the three schwannomas
studied showed gain on 11q167. The pathogenesis of gastric schwannomas may differ from
that of vestibular ones since these three gastric schwannomas showed no losses on 22q167,
and gastric schwannomas have not been reported in NF2 patients.
Meningioma is the second most common tumor in NF2 patients, seen in about 50% of
cases123. The same genetic defect, i.e., inactivation of the NF2 gene, is postulated to be the
major event in the development of both schwannomas and meningiomas109. In a recent CGH
study, atypical (grade II) and anaplastic (grade III) meningiomas showed frequent allelic losses
on chromosome arms 1p, 6q, 9p, 10q, and 14q, suggesting that progression-associated genes
may lie at these loci193. In the present schwannoma series, no losses on chromosomes 1, 9,
10, and 14 were detected, and only one NF2 schwannoma showed loss on 6q. Thus, apart
from the NF2 gene defect, chromosomal alterations appear to be different in schwannomas
and meningiomas.
To date, inactivating NF2 mutations have been detected in up to 60% of
schwannomas74, suggesting superimposed secondary or alternative genetic abnormalities in
schwannomas lacking NF2 gene defects. Based on the present CGH analysis, chromosome 22
seems to be the only genomic region consistently involved in the pathogenesis of
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schwannomas. The NF2 gene may, in fact, be inactivated in all schwannomas since current
mutation detection methods are not 100% sensitive74 and promoter and large intronic regions
of the NF2 gene have not been screened183. In addition, the universal loss of merlin
immunoreactivity in schwannomas has been well documented67,69,162,181. Loss of merlin
expression has also been demonstrated in schwannomas lacking genetic evidence of biallelic
NF2 gene inactivation183. Interestingly, Bruder et al. reported recently a small group of
sporadic schwannomas with interstitial deletions on 22q outside the NF2 locus and with no
detectable mutations in the NF2 gene22. This finding points to a possible role of an additional
(modifier) gene on 22q, which, in cooperation with the NF2 tumor suppressor, may cause
schwannomas.
4.4 Population-Based Analysis of Sporadic and Neurofibromatosis 2-Associated
Meningiomas and Schwannomas (IV)
Approximately 1% (N = 7/823) of the meningioma patients had multiple meningiomas
in association with NF2, and 4% (N = 29/823) had meningiomatosis without NF2 (Table 7).
Approximately 3% (N = 12/455) of the schwannoma patients had multiple schwannomas in
association with NF2, and 2% (N = 11/455) had schwannomatosis without NF2.
Computer-based search in the PRC database revealed 4,218 relatives for the 1,221
patients with a single schwannoma or meningioma without clinical NF2. Manual construction
of pedigrees for the 40 patients with multiple meningiomas or schwannomas but no NF2
resulted in 730 relatives for the 40 index cases in the search for familial meningiomatosis and
schwannomatosis.
Table 8 summarizes the clinical characteristics of the patients with a single
meningioma (N = 788) or schwannoma (N = 433). Linkage from PRC to FCR identified one
meningioma patient (1/788) with a relative with a meningioma (1/2,322) but the overall
pedigree (N = 18) and cranial MRI of the index patient excluded classic NF2. This pairing
was regarded as coincidental.
Four schwannoma patients (4/433) had a relative (4/1,896) with a meningioma (N = 3)
or schwannoma (N = 1). MRI excluded classic NF2 in two of them, whereas in the other two
no adequate cranial and spinal imaging had been performed. Pedigree analysis of these four
patients did not reveal any other affected relatives among 120 screened. Therefore these
pairings were also regarded as coincidental.
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Meningiomatosis patients (N = 29) included six old patients (median age 85 years,
range 77-91 years) who were diagnosed incidentally at autopsy (Table 9). After exclusion of
these six cases, the median ages of the patients with single (N = 788) and multiple
meningiomas (N = 23) were similar (58 vs. 61 years). Likewise, the female/male-ratio (2.9 vs.
3.6, p >0.05) and the proportion of grade II-III meningiomas (8% vs. 9%, p >0.05) did not
differ significantly. None of the meningiomatosis patients had history of schwannoma,
ependymoma, glioma, or any other NF2-associated lesion. Linkage to FCR was performed for
491 relatives, and no meningiomatosis families were found. The annual age-adjusted (World
Standard Population) incidence of meningiomatosis was 1.2/1,000,000.
Eleven patients were identified who fulfilled the criteria of definite or probable
schwannomatosis (Table 9). The patients with single (N = 434) and multiple schwannomas (N
= 11) did not differ significantly in median age (48 years vs. 45 years, p >0.05) nor in
female/male-ratio (1.4 vs. 0.8, p >0.05). Linkage to FCR was performed for 244 relatives, and
two potential schwannomatosis families were found. The annual age-adjusted (World
Standard Population) incidence of schwannomatosis was 0.55/1,000,000 (1/1,808,300) in the
study area.
The basic series of 1,278 patients included 10 novel NF2 cases (including four familial
cases from three different families) diagnosed between 1985 and 1995 and seven NF2 cases
already diagnosed before the study period. These 17 NF2 patients were younger (median age
36 years) than the sporadic patients with single or multiple schwannomas (p <0.01; p = 0.04)
or meningiomas (p <0.01; p <0.01). There were eight familial NF2 cases (five female, three
male) from five different families. Four women had a severe form of NF2 with multiple
intracranial and spinal schwannomas and meningiomas. All the NF2 patients fulfilled the
defined NF2 criteria.
The annual age-adjusted (World Standard Population) incidence of the new diagnoses
of NF2 was 0.50/1,000,000 (1/2,004,000). The proportion of NF2 cases among newborn was
estimated as previously published44. The median birth year of the 10 NF2 cases diagnosed
from 1985 to 1995 was 1955 (range 1933-1976). On the basis of the annual birth rates in
southern Finland from 1950 to 1960 (874,103 live births), the occurrence of NF2 would be
1/87,410 live births.
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Table 7
Familial Ties Among 1,278 Patients with Histologically Verified Meningioma(s) or Schwannoma(s).
Patients with
Single Tumor
N = 1221 (96%)
Patients with
Multiple Tumors
N = 40 (3%)
Patients with
NF2
N = 17 (1%)
Sporadic
N = 1216
Coincidentala
N = 5
Sporadic
N = 38
Familial
N = 2
Sporadicb
N = 9
Familial
N = 8
Patients with Meningiomas, N = 823 787 (96%) 1 29 (4%) 0 7 (1%) 0
Patients with Schwannomas, N = 455 429 (95%) 4 (1%) 9 (2%) 2 4 (1%) 8 (2%)
aFour patients with a relative with single meningioma (N = 4) or schwannoma (N = 1) without any other NF2 features
bTwo sporadic NF2 patients had both meningiomas and schwannomas removed during the study period
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Table 8
Clinical Characteristics of 1,221 Patients with a Single Sporadic Meningioma or Schwannoma and Corresponding Annual Incidence Rates per
100,000 Population.
Patients with a Meningioma Patients with a Schwannoma
Site All Intracranial Spinal All Intracranial Spinal Peripherala
N 788 715 (91%) 74 (9%) 433 252 (58%) 69 (16%) 112 (26%)
Ageb (range) 58 (17-99) 57 64 48 (16-86) 50 46 46
Incidence (F/M) 3.4 (4.7/2.0) 3.1 (4.2/1.9) 0.3 (0.5/0.1) 2.1 (2.2/1.9) 1.2 (1.3/1.0) 0.3 (0.3/0.4) 0.6 (0.6/0.5)
F/M Ratio 2.9 (588/200) 2.8 (525/190) 5.7 (63/11) 1.4 (251/182) 1.5 (153/99) 0.8 (30/39) 1.6 (69/43)
Gradec of
Tumor
I
II
III
723 (92%)
61 (8%)
4 (1%)
652 (92%)
59 (8%)
4 (1%)
72 (97%)
2 (3%)
0
428 (99%)
4 (1%)
1
249 (99%)
3 (1%)
0
68 (99%)
1 (1%)
0
111 (99%)
0
1 (1%)
aIncludes peripheral nerve, nerve plexus and subcutaneous schwannomas
bMedian age (years) at the time of the histological verification
cHistological grade according to the WHO classification (Zülch 1979206 and Kleihues et al. 199386)
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Table 9
Clinical Characteristics of 40 Patients with Meningiomatosis or Schwannomatosis and
Corresponding Annual Incidence Rates per 100,000 Population.
Variable Meningiomatosis Patientsa Schwannomatosis Patients
N 29 (23) 11
Sex (F/M)
F/M  Ratio
23/6 (18/5)
3.8 (3.6)
5/6
0.83
Incidence (F/M) 0.17/0.06 (0.15/0.05) 0.06/0.06
Ageb (years)
Range (years)
66 (61)
45-91 (45-82)
45
20-63
Distribution of Tumors
Intracranial
Spinal
Peripheral
29
2c
0
1
5
5
N of Removed Tumors
Graded
I
II
III
50
48
1
1
26
26
0
0
aSymptomatic meningiomatosis patients are presented in parentheses (six autopsied cases excluded)
bMedian age (years) at time of the first surgery
cTwo patients had both intracranial and spinal meningiomas
dGrade according to the WHO classification (Zülch 1979206 and Kleihues et al. 199386)
A diagnosis of NF2 has profound implications both for the patient and his/her
relatives. Usually the distinction is readily made between sporadic unilateral vestibular
schwannoma and familial NF2 with BVSs and other NF2 signs. There are still a number of
patients who do not fulfill the diagnostic criteria of NF2 but in whom the possibility of NF2
seems real. These include patients who develop a single meningioma or schwannoma and
have a family history of isolated schwannomas or meningiomas. Patients with
schwannomatosis or meningiomatosis are possible NF2 cases, particularly if they have a
family history of NF2-related tumors. One aim of this study was to evaluate the proportions of
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these patient groups and their relations to NF2 in a defined population. In the absence of
classic NF2, meningiomas were multiple (meningiomatosis) in 4% of meningioma patients
and schwannomas were multiple (schwannomatosis) in 2% of schwannoma patients. The
patients with meningiomatosis or schwannomatosis resembled those with single tumors in
terms of average age at diagnosis, female/male-ratio, and proportion of malignant forms. The
results indicate that familial meningiomatosis, if it truly exists, is very rare (0 of 823 patients
with meningioma) and familial schwannomatosis uncommon (2 of 455 patients with
schwannoma) in the study population. The present data also suggest that meningiomas and
schwannomas may coincide in the relatives of patients with apparently sporadic single
meningioma (1 of 788) or schwannoma (4 of 433).
4.4.1 Methodological Considerations (IV)
The present series encompasses virtually all intracranial and spinal meningiomas and
schwannomas diagnosed and histologically verified in southern Finland from 1985 to 1995,
because all benign intracranial and spinal tumors must be reported to the FCR. Several
overlapping search strategies were used to collect the data, the sources including FCR,
hospital discharge records, neurosurgical operation lists and reports, neuroradiology reports,
and pathology and autopsy reports. Unfortunately, there is no obligation to report benign
peripheral or subcutaneous tumors to FCR, and therefore the incidence of peripheral and
subcutaneous schwannomas is merely a hospital-based estimate. Some schwannomatosis
patients with a disease localized to the subcutaneous tissue may have been missed. The PRC
database was used to identify relatives for the index patients, and their data were linked with
FCR files. First-degree relatives were easily obtained for patients under 45 years of age, but
due to the structure of PRC database (see Chapter 3.5.2) few relatives were found for older
patients. However, detailed pedigrees with all first- and second-degree relatives were
constructed using parish records for patients with NF2, meningiomatosis, or schwannomatosis
and for patients with a relative with a meningioma or schwannoma.
4.4.2 Schwannomatosis (IV)
Schwannomatosis is a recently introduced clinical entity. Most schwannomatosis
patients are middle aged at presentation115,175, and in the present series they were older than
NF2 patients whose mean age at diagnosis is 28 years43. No previous population-based data
exist of the incidence of schwannomatosis. As a unique finding, the annual incidence of
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schwannomatosis was estimated to be 0.55/1,000,000 (1/1,808,300). Two schwannomatosis
families were found among the 455 schwannoma patients studied. The present study supports
previous reports45,73 in that there are cases of familial schwannomatosis in population. Their
genetic background, important in terms of schwannoma biology, remains to be settled.
4.4.3 Coincidental Cases (IV)
Patients who develop a single meningioma or schwannoma and have a family history
of isolated schwannomas or meningiomas are possible NF2 cases. In the present series, five
such individuals were found, each one having a first-degree relative with meningioma or
schwannoma. Meningiomas are not uncommon since they are encountered in 1.4% of
autopsies149, mostly as incidental findings. A single meningioma or schwannoma may
sometimes appear to be familial but is likely to be coincidental. Wu et al.204 showed that
when a patient with a single vestibular schwannoma and family history of a single NF2 related
tumor is thoroughly investigated, usually no additional NF2 features nor NF2 germline
mutations are detected.
4.4.4 Occurrence of NF2 (IV)
The true occurrence of NF2 in a population is difficult to assess for several reasons.
NF2 is a rare condition and therefore calculations of the occurrence are based on small
numbers of patients. The diagnostic window of NF2 is rather narrow between clinical
presentation (mean age at diagnosis 28 years)43,135 and death (mean age at death 39
years)43,135. Approximately half the NF2 cases are familial, and in families with a mild form
of the disease several asymptomatic NF2 patients may become known along with the
proband160. Because NF2 is an inborn condition, the number of NF2 cases per newborn is a
more appropriate measure than annual incidence, which reflects the number of new diagnoses
per population over time. Only one epidemiological study on NF2 has been published
previously44. From 1980 to 1989, 17 NF2 patients were diagnosed in the northwest region in
England in a population of 4,016,100, and Evans et al.44 assessed the birth occurrence to be
1/40,562 which is clearly higher than the 1/87,410 in the present series. Evans et al.44 visited
NF2 patients personally, and asymptomatic relatives were screened using cranial CT or MRI
scans, whereas the present series was based on the existing medical records and files. More
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accurate estimates are only obtainable by a uniform NF2 screening program in a large
population.
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5 CONCLUSIONS
1. NF2 schwannomas had a significantly higher proliferation potential, as assessed by MIB-1
labeling, than did sporadic age-matched tumors.
2. NF2 meningiomas showed more mitotic figures and nuclear pleomorphism than did
sporadic meningiomas but no other specific histological features distinguishing NF2
meningiomas from the sporadic tumors were observed. Meningothelial, fibrous, and
transitional subtypes occurred equally among NF2 meningiomas and sporadic meningiomas.
Proliferation potential was significantly higher in meningiomas from NF2 patients than in
sporadic meningiomas from age- and sex-matched non-NF2 patients. The higher proliferation
potential of NF2 schwannomas and meningiomas compared with sporadic tumors reflects
differences in the molecular biology between these two groups and may contribute to the
earlier onset, multiplicity, and more aggressive behavior of NF2-associated tumors.
3. The most common genetic alteration detected by CGH in both NF2-associated and sporadic
schwannomas was loss on 22q, found in about one-third of the schwannomas. No consistent
changes were detected in other chromosomal regions. The overall number of genetic
aberrations was similar in NF2-associated and sporadic schwannomas, and only minor
differences in aberrations were detected. These results suggest that the chromosome 22 region
with the NF2 gene is the only chromosomal region consistently involved in the pathogenesis
of schwannomas.
4. In the absence of classic NF2, meningiomas were multiple (meningiomatosis) in 4% of
meningioma patients, and schwannomas were multiple (schwannomatosis) in 2% of
schwannoma patients. The patients with meningiomatosis and schwannomatosis resembled
those with single tumors in terms of average age at diagnosis, female/male-ratio, and
proportion of malignant forms. Familial meningiomatosis, if it truly exists, is very rare (none
per 823 meningioma patients), and familial schwannomatosis is uncommon (two per 455
schwannoma patients) in southern Finland. The birth occurrence of NF2 in southern Finland
was 1/87,410.
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6 SUMMARY
Schwannomas and meningiomas are usually benign tumors, in most cases curable by
seemingly complete removal. They occur either as single sporadic tumors in otherwise healthy
individuals in the fourth to sixth decades of life or as multiple tumors at an early age as part of
the autosomal dominant genetic disorder neurofibromatosis 2 (NF2). The hallmark feature of
NF2 is bilateral vestibular schwannomas. Previous clinical and histological series have
suggested biological differences between NF2-associated and sporadic schwannomas and
meningiomas. Multiplicity, a lobular growth pattern, and invasiveness are typical features of
NF2 schwannomas. Consequently, preservation of the continuity and function of the facial and
cochlear nerves during surgery has been more difficult in NF2. Previously histological features
have not been compared systematically between NF2 and sporadic meningiomas but the more
aggressive clinical course of NF2 meningiomas compared with sporadic cases has been noted.
Multiplicity partly explains why many NF2 patients have a shortened life-span but it hardly
accounts for the clinical experience that NF2 schwannomas and meningiomas are more
aggressive.
The diagnosis of NF2 is not always clear since there is a heterogeneous and poorly
defined group of patients who do not have BVSs but present with other features suggestive of
NF2, namely (1) multiple meningiomas or schwannomas and/or (2) meningioma(s) or
schwannomas(s) in their relatives. These cases are thought to be rather uncommon but they
present problems for prognosis, therapy, follow-up, and genetic counseling.
The present study was undertaken to compare NF2-associated and sporadic
schwannomas and meningiomas in detail. The proliferation potential of NF2-associated and
sporadic schwannomas and meningiomas were compared using MIB-1 labeling. Novel genetic
alterations were searched in schwannomas, and genetic alterations in NF2-associate and
sporadic schwannomas were compared using comparative genomic hybridization (CGH). An
extensive population-based study was conducted to assess the proportions of meningiomatosis
and schwannomatosis among patients with single tumors, and their relation to NF2.
NF2-associated schwannomas and meningiomas had a significantly higher
proliferation potential, as assessed by MIB-1 labeling, compared with sporadic age-matched
tumors. The higher proliferation potential of NF2 schwannomas and meningiomas compared
with sporadic tumors may reflect differences in the molecular biology may be contribute to the
earlier onset, multiplicity, and more aggressive behavior of NF2-associated tumors.
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The most common genetic alteration detected by CGH in both NF2-associated and
sporadic schwannomas was loss on 22q, detected in about one-third of schwannomas. No
consistent changes were detected in other chromosomal regions. This result lends support to
the hypothesis that loss of the chromosome 22 harboring the NF2 gene is the only consistent
genetic alteration in schwannomas.
In the absence of classic NF2, meningiomas were multiple (meningiomatosis) in 4%
meningioma patients, and schwannomas were multiple (schwannomatosis) in 2% of
schwannoma patients. The patients with meningiomatosis and schwannomatosis resembled
those with single tumors in terms of average age at diagnosis, female/male-ratio, and
proportion of malignant forms. Familial meningiomatosis, if it truly exists, is very rare (none
per 823 meningioma patients), and familial schwannomatosis is uncommon (two per 455
schwannoma patients). The occurrence of NF2 at birth in southern Finland was 1 per 87,410
live births.
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